GlassScriptPhysician profile
Miriam S Gerber
NPI 1295777993
$3,005.73
in general payments reported to CMS, 2019-2025
28 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $317 · 2023: $846 · 2024: $1,046 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $615.95 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $511.24 | 2021-2025 | |
| Pfizer INC. | $400.06 | 2023-2025 | |
| Lilly USA, LLC | $271.02 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $155.98 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.69 | 2023-2024 | Xifaxan, Trulance |
| Shield Therapeutics INC | $115.62 | 2023-2025 | Accrufer |
| Abbott Laboratories | $91.25 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $71.20 | 2022-2024 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $66.23 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Biohaven Pharmaceuticals, INC. | $56.57 | 2021 | |
| Exeltis, USA INC. | $53.31 | 2021-2024 | Slynd |
| Astellas Pharma US INC | $45.67 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $45.26 | 2022 | |
| Seqirus USA INC | $43.43 | 2021-2025 | Flucelvax, Fluad |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $41.15 | 2025 | Voquezna |
| Triad Life Sciences INC. | $33.04 | 2022 | |
| Lundbeck LLC | $29.81 | 2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $29.76 | 2023 | Quviviq |
| Vistapharm, INC. | $26.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.01 | 2023 | |
| Dexcom, INC. | $24.27 | 2023 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $21.63 | 2021 | |
| Glaxosmithkline, LLC. | $20.97 | 2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $20.18 | 2023 | Vaxelis, Rotateq, Vaxneuvance |
| Gilead Sciences, INC. | $19.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.22 | 2024 | Trintellix |
| Genentech USA, INC. | $10.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.